Literature DB >> 17965746

Delta9-tetrahydrocannabinol (THC) and AM 404 protect against cerebral ischaemia in gerbils through a mechanism involving cannabinoid and opioid receptors.

A Zani1, D Braida, V Capurro, M Sala.   

Abstract

BACKGROUND AND
PURPOSE: It has been suggested that the endocannabinoid system elicits neuroprotection against excitotoxic brain damage. In the present study the therapeutic potential of AM 404 on ischaemia-induced neuronal injury was investigated in vivo and compared with that of the classical cannabinoid receptor type 1 (CB1) agonist, delta 9-tetraydrocannabinol (THC), using a model of transient global cerebral ischaemia in the gerbil. EXPERIMENTAL APPROACH: The effects of AM 404 (0.015-2 mg kg(-1)) and THC (0.05-2 mg kg(-1)), given 5 min after ischaemia, were measured from 1 h to 7 days in terms of electroencephalographic (EEG) total spectral power, spontaneous motor activity, memory function, rectal temperature and hippocampal CA1 neuronal count. KEY
RESULTS: Over the dose range tested, AM 404 (2 mg kg(-1)) and THC (1 mg kg(-1)) completely reversed the ischaemia-induced behavioural, EEG and histological damage. Only THC (1 and 2 mg kg(-1)) induced a decrease of body temperature. Pretreatment with the selective CB1 receptor antagonist, AM 251 (1 mg kg(-1)) and the opioid antagonist, naloxone (2 mg kg(-1)) reversed the protective effect induced by both AM 404 and THC while the TRPV1 vanilloid antagonist, capsazepine (0.01 mg kg(-1)), was ineffective. CONCLUSIONS AND IMPLICATIONS: Our findings demonstrate that AM 404 and THC reduce neuronal damage caused by bilateral carotid occlusion in gerbils and that this protection is mediated through an interaction with CB1 and opioid receptors. Endocannabinoids might form the basis for the development of new neuroprotective drugs useful for the treatment of stroke and other neurodegenerative pathologies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17965746      PMCID: PMC2189998          DOI: 10.1038/sj.bjp.0707514

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  82 in total

1.  Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test.

Authors:  Matthew N Hill; Boris B Gorzalka
Journal:  Eur Neuropsychopharmacol       Date:  2005-12       Impact factor: 4.600

Review 2.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

Review 3.  Cannabinoids: between neuroprotection and neurotoxicity.

Authors:  Yosef Sarne; Raphael Mechoulam
Journal:  Curr Drug Targets CNS Neurol Disord       Date:  2005-12

4.  Protective effects of Delta(9)-tetrahydrocannabinol against N-methyl-d-aspartate-induced AF5 cell death.

Authors:  Jia Chen; Chun-Ting Lee; Stacie Errico; Xiaolin Deng; Jean L Cadet; William J Freed
Journal:  Brain Res Mol Brain Res       Date:  2005-04-04

5.  Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.

Authors:  Isabel Lastres-Becker; Francisco Molina-Holgado; José A Ramos; Raphael Mechoulam; Javier Fernández-Ruiz
Journal:  Neurobiol Dis       Date:  2005 Jun-Jul       Impact factor: 5.996

6.  Capsaicin exhibits neuroprotective effects in a model of transient global cerebral ischemia in Mongolian gerbils.

Authors:  Simona Pegorini; Daniela Braida; Chiara Verzoni; Chiara Guerini-Rocco; Gian Giacomo Consalez; Laura Croci; Mariaelvina Sala
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

7.  Delta9-tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats.

Authors:  Daniela Braida; Stefania Iosuè; Simona Pegorini; Mariaelvina Sala
Journal:  Eur J Pharmacol       Date:  2004-12-03       Impact factor: 4.432

8.  Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity.

Authors:  David A Karanian; Queenie B Brown; Alexandros Makriyannis; Therese A Kosten; Ben A Bahr
Journal:  J Neurosci       Date:  2005-08-24       Impact factor: 6.167

Review 9.  The endocannabinoid system: physiology and pharmacology.

Authors:  Fernando Rodríguez de Fonseca; Ignacio Del Arco; Francisco Javier Bermudez-Silva; Ainhoa Bilbao; Andrea Cippitelli; Miguel Navarro
Journal:  Alcohol Alcohol       Date:  2004-11-18       Impact factor: 2.826

10.  Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis.

Authors:  Sachin Patel; Craig T Roelke; David J Rademacher; William E Cullinan; Cecilia J Hillard
Journal:  Endocrinology       Date:  2004-08-26       Impact factor: 4.736

View more
  10 in total

Review 1.  Cannabinoid as a neuroprotective strategy in perinatal hypoxic-ischemic injury.

Authors:  Daniel Alonso-Alconada; Antonia Alvarez; Enrique Hilario
Journal:  Neurosci Bull       Date:  2011-08       Impact factor: 5.203

Review 2.  On the Biomedical Properties of Endocannabinoid Degradation and Reuptake Inhibitors: Pre-clinical and Clinical Evidence.

Authors:  Karen Jaqueline Paredes-Ruiz; Karla Chavira-Ramos; Mario Orozco-Morales; Cimen Karasu; Alexey A Tinkov; Michael Aschner; Abel Santamaría; Ana Laura Colín-González
Journal:  Neurotox Res       Date:  2021-11-06       Impact factor: 3.911

Review 3.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 4.  Role of cannabinoids and endocannabinoids in cerebral ischemia.

Authors:  Cecilia J Hillard
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 5.  Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications.

Authors:  Javier Fernández-Ruiz; María A Moro; José Martínez-Orgado
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

6.  Clinical studies and anti-inflammatory mechanisms of treatments.

Authors:  Jacqueline A French; Matthias Koepp; Yvonne Naegelin; Federico Vigevano; Stéphane Auvin; Jong M Rho; Evan Rosenberg; Orrin Devinsky; Peder S Olofsson; Marc A Dichter
Journal:  Epilepsia       Date:  2017-07       Impact factor: 5.864

7.  Prolonged exposure to WIN55,212-2 causes downregulation of the CB1 receptor and the development of tolerance to its anticonvulsant effects in the hippocampal neuronal culture model of acquired epilepsy.

Authors:  Robert E Blair; Laxmikant S Deshpande; Sompong Sombati; Maurice R Elphick; Billy R Martin; Robert J DeLorenzo
Journal:  Neuropharmacology       Date:  2009-06-18       Impact factor: 5.250

Review 8.  Cannabinoids and Dementia: A Review of Clinical and Preclinical Data.

Authors:  Sebastian Walther; Michael Halpern
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-17

9.  AM404, paracetamol metabolite, prevents prostaglandin synthesis in activated microglia by inhibiting COX activity.

Authors:  Soraya Wilke Saliba; Ariel R Marcotegui; Ellen Fortwängler; Johannes Ditrich; Juan Carlos Perazzo; Eduardo Muñoz; Antônio Carlos Pinheiro de Oliveira; Bernd L Fiebich
Journal:  J Neuroinflammation       Date:  2017-12-13       Impact factor: 8.322

10.  Neuroprotective Effect of AM404 Against NMDA-Induced Hippocampal Excitotoxicity.

Authors:  Soraya Wilke Saliba; Tiziana Bonifacino; Tsvetan Serchov; Giambattista Bonanno; Antônio Carlos Pinheiro de Oliveira; Bernd L Fiebich
Journal:  Front Cell Neurosci       Date:  2019-12-20       Impact factor: 5.505

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.